Biomarin Pharmaceuticals (BMRN)

$54.59 -0.48 (-0.87%)
Market Cap 10.77B
Revenue (ttm) 2.85B
Net Income (ttm) 426.86M
EPS (ttm) N/A
PE Ratio 19.23
Forward PE 12.25
Profit Margin 14.96%
Debt to Equity Ratio 0.00
Volume 2,076,400
Avg Vol 2,857,292
Day's Range N/A - N/A
Shares Out 192.11M
Stochastic %K 9%
Beta 0.27
Analysts Strong Sell
Price Target $89.96

Company Profile

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic pep...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 506 6700
Address:
770 Lindaro Street, San Rafael, United States
CaptainAmrica
CaptainAmrica Jan. 15 at 7:07 PM
$BMRN... This company is ripe for a major turnaround...Initiated.
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jan. 15 at 12:55 PM
$BMRN back in at $55. LETS ROCK TO PDUFA
0 · Reply
Ohzipit
Ohzipit Jan. 14 at 7:00 PM
$BMRN RJ post earnings comments. Solid Q4, Pipeline Progress Kicks Off Big 2026 remains Outperform base case target $100 bull case $133
0 · Reply
nepepe
nepepe Jan. 14 at 1:53 PM
$ACRV $BMRN $LLY $REGN $VRTX
0 · Reply
trading_momentum_x
trading_momentum_x Jan. 14 at 4:34 AM
$BMRN Biomarin Pharma - A luckluster Q3 earnings has created a great opportuntiy to accumulate stock. Riskier healthcare play, but the risk to reward is hard to pass up.
0 · Reply
DairyQueen505
DairyQueen505 Jan. 14 at 2:40 AM
$BMRN this chart is wild. The stock price is disconnected from the success of the company and actual business. Is the market crazy or are shareholders for continuing to put up with this bullshit?
0 · Reply
DairyQueen505
DairyQueen505 Jan. 13 at 9:21 PM
$BMRN buying opportunity or dead money?
0 · Reply
Maccers
Maccers Jan. 13 at 9:17 PM
$BMRN Buying opportunity
0 · Reply
WB_Bull
WB_Bull Jan. 13 at 9:08 PM
$BMRN I was invested in that stock 14 years ago. As they sold the licence of Firdapse to CPRX (2012) i changed my investment to CPRX $0.50 per share Now i'm very happy with share price of $22 2 great products with high revenue and PT of $35 Biomarin is dead money for 10 years now!
0 · Reply
DairyQueen505
DairyQueen505 Jan. 13 at 9:00 PM
$BMRN brutal day. No love for this one despite all the tailwinds. Who knows how low it can go until market wakes up to it.
0 · Reply
Latest News on BMRN
BioMarin Pharmaceutical Inc. (BMRN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 6:25 PM EST - 4 days ago

BioMarin Pharmaceutical Inc. (BMRN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

BioMarin Appoints Arpit Davé Chief Digital and Information Officer

Jan 12, 2026, 4:05 PM EST - 4 days ago

BioMarin Appoints Arpit Davé Chief Digital and Information Officer

BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA

Jan 8, 2026, 4:05 PM EST - 8 days ago

BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA

Veeva and BioMarin Form Long-Term Strategic Partnership

Jan 8, 2026, 8:30 AM EST - 8 days ago

Veeva and BioMarin Form Long-Term Strategic Partnership

VEEV

Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD

Dec 26, 2025, 3:28 PM EST - 21 days ago

Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD

FOLD

What's Going On With BioMarin Stock On Tuesday?

Dec 23, 2025, 1:05 PM EST - 24 days ago

What's Going On With BioMarin Stock On Tuesday?

BioMarin: Amicus Buyout Sparks My Enthusiasm

Dec 22, 2025, 3:15 PM EST - 25 days ago

BioMarin: Amicus Buyout Sparks My Enthusiasm

FOLD

BioMarin Pharmaceutical Inc. (BMRN) M&A Call Transcript

Dec 19, 2025, 11:27 AM EST - 4 weeks ago

BioMarin Pharmaceutical Inc. (BMRN) M&A Call Transcript

BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping.

Dec 19, 2025, 10:55 AM EST - 4 weeks ago

BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping.

FOLD

BioMarin to Buy Amicus Therapeutics for $4.8 Billion

Dec 19, 2025, 8:13 AM EST - 4 weeks ago

BioMarin to Buy Amicus Therapeutics for $4.8 Billion

FOLD

BioMarin to acquire Amicus Therapeutics for $4.8 Billion

Dec 19, 2025, 7:56 AM EST - 4 weeks ago

BioMarin to acquire Amicus Therapeutics for $4.8 Billion

FOLD

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook

Dec 19, 2025, 7:45 AM EST - 4 weeks ago

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook

FOLD

BioMarin Pharmaceutical Inc. (BMRN) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 18, 2025, 9:08 AM EST - 2 months ago

BioMarin Pharmaceutical Inc. (BMRN) Presents at Jefferies London Healthcare Conference 2025 Transcript

BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England

Nov 11, 2025, 9:00 AM EST - 2 months ago

BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England

FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria

Oct 29, 2025, 9:00 AM EDT - 2 months ago

FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria

Biomarin Pharmaceutical Analysts Cut Their Forecasts After Downbeat Earnings

Oct 28, 2025, 9:48 AM EDT - 2 months ago

Biomarin Pharmaceutical Analysts Cut Their Forecasts After Downbeat Earnings

BioMarin Pharmaceuticals - Growing Numbers, Falling Expectations

Oct 28, 2025, 6:58 AM EDT - 2 months ago

BioMarin Pharmaceuticals - Growing Numbers, Falling Expectations

BioMarin Pharmaceutical Inc. (BMRN) Q3 2025 Earnings Call Transcript

Oct 27, 2025, 8:17 PM EDT - 2 months ago

BioMarin Pharmaceutical Inc. (BMRN) Q3 2025 Earnings Call Transcript

BioMarin Pharma plans to divest struggling gene therapy

Oct 27, 2025, 6:34 PM EDT - 2 months ago

BioMarin Pharma plans to divest struggling gene therapy

BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update

Oct 27, 2025, 4:03 PM EDT - 2 months ago

BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update

BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET

Oct 22, 2025, 4:05 PM EDT - 3 months ago

BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET

BioMarin: Valuation, Growth, And The Pipeline May Outweigh TransCon Competition And Regulatory Risks

Sep 30, 2025, 7:01 AM EDT - 3 months ago

BioMarin: Valuation, Growth, And The Pipeline May Outweigh TransCon Competition And Regulatory Risks

BioMarin Pharmaceutical Inc. (BMRN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 4:46 PM EDT - 4 months ago

BioMarin Pharmaceutical Inc. (BMRN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment

Sep 8, 2025, 1:56 PM EDT - 4 months ago

PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment

PTCT

BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting

Sep 8, 2025, 9:00 AM EDT - 4 months ago

BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting

BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism

Sep 6, 2025, 11:05 AM EDT - 4 months ago

BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism

BioMarin Pharmaceutical Inc. (BMRN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Sep 4, 2025, 11:27 AM EDT - 4 months ago

BioMarin Pharmaceutical Inc. (BMRN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

Sep 3, 2025, 3:32 PM EDT - 4 months ago

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

ARGX BBH CYTK IBB XBI

BioMarin Pharmaceutical Inc. (BMRN) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 3, 2025, 11:01 AM EDT - 4 months ago

BioMarin Pharmaceutical Inc. (BMRN) Presents At Cantor Global Healthcare Conference 2025 Transcript

BioMarin to Participate in Upcoming Investor Conferences

Aug 27, 2025, 9:00 AM EDT - 5 months ago

BioMarin to Participate in Upcoming Investor Conferences

BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401

Aug 5, 2025, 4:20 PM EDT - 5 months ago

BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401

INZY

BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030

Aug 5, 2025, 1:11 PM EDT - 5 months ago

BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030

BioMarin Pharmaceutical Inc. (BMRN) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 11:04 PM EDT - 5 months ago

BioMarin Pharmaceutical Inc. (BMRN) Q2 2025 Earnings Call Transcript

BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS

Aug 4, 2025, 4:02 PM EDT - 5 months ago

BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS

BioMarin Announces Appointment of Ian T. Clark to Board of Directors

Aug 1, 2025, 9:00 AM EDT - 6 months ago

BioMarin Announces Appointment of Ian T. Clark to Board of Directors

BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET

Jul 22, 2025, 9:00 AM EDT - 6 months ago

BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET

It is time for a move higher in biotech, says Mizuho's Jared Holz

Jul 7, 2025, 6:29 PM EDT - 6 months ago

It is time for a move higher in biotech, says Mizuho's Jared Holz

BBIO GILD INSM XBI

BioMarin Announces Completion of Acquisition of Inozyme

Jul 1, 2025, 8:45 AM EDT - 7 months ago

BioMarin Announces Completion of Acquisition of Inozyme

INZY

BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress

Jun 24, 2025, 9:00 AM EDT - 7 months ago

BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress

INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY

May 21, 2025, 5:56 PM EDT - 8 months ago

INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY

INZY

BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

May 16, 2025, 7:30 AM EDT - 8 months ago

BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

INZY

BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings

May 12, 2025, 9:05 AM EDT - 8 months ago

BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings

BioMarin Pharmaceutical Inc. (BMRN) Q1 2025 Earnings Call Transcript

May 1, 2025, 7:25 PM EDT - 9 months ago

BioMarin Pharmaceutical Inc. (BMRN) Q1 2025 Earnings Call Transcript

BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance

May 1, 2025, 4:05 PM EDT - 9 months ago

BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance

BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET

Apr 17, 2025, 9:00 AM EDT - 9 months ago

BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET

BioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label Expansion

Apr 3, 2025, 3:37 PM EDT - 10 months ago

BioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label Expansion

BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria

Apr 2, 2025, 9:00 AM EDT - 10 months ago

BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria

BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

Mar 20, 2025, 9:00 AM EDT - 10 months ago

BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA

Feb 25, 2025, 9:00 AM EST - 11 months ago

BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA

BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors

Feb 24, 2025, 4:05 PM EST - 11 months ago

BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors

CaptainAmrica
CaptainAmrica Jan. 15 at 7:07 PM
$BMRN... This company is ripe for a major turnaround...Initiated.
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jan. 15 at 12:55 PM
$BMRN back in at $55. LETS ROCK TO PDUFA
0 · Reply
Ohzipit
Ohzipit Jan. 14 at 7:00 PM
$BMRN RJ post earnings comments. Solid Q4, Pipeline Progress Kicks Off Big 2026 remains Outperform base case target $100 bull case $133
0 · Reply
nepepe
nepepe Jan. 14 at 1:53 PM
$ACRV $BMRN $LLY $REGN $VRTX
0 · Reply
trading_momentum_x
trading_momentum_x Jan. 14 at 4:34 AM
$BMRN Biomarin Pharma - A luckluster Q3 earnings has created a great opportuntiy to accumulate stock. Riskier healthcare play, but the risk to reward is hard to pass up.
0 · Reply
DairyQueen505
DairyQueen505 Jan. 14 at 2:40 AM
$BMRN this chart is wild. The stock price is disconnected from the success of the company and actual business. Is the market crazy or are shareholders for continuing to put up with this bullshit?
0 · Reply
DairyQueen505
DairyQueen505 Jan. 13 at 9:21 PM
$BMRN buying opportunity or dead money?
0 · Reply
Maccers
Maccers Jan. 13 at 9:17 PM
$BMRN Buying opportunity
0 · Reply
WB_Bull
WB_Bull Jan. 13 at 9:08 PM
$BMRN I was invested in that stock 14 years ago. As they sold the licence of Firdapse to CPRX (2012) i changed my investment to CPRX $0.50 per share Now i'm very happy with share price of $22 2 great products with high revenue and PT of $35 Biomarin is dead money for 10 years now!
0 · Reply
DairyQueen505
DairyQueen505 Jan. 13 at 9:00 PM
$BMRN brutal day. No love for this one despite all the tailwinds. Who knows how low it can go until market wakes up to it.
0 · Reply
tradeitbetit
tradeitbetit Jan. 13 at 8:55 PM
$BMRN gets upgraded - goes down Gets good news - goes down Announces 5x better results for DMD patients than $SRPT theraphy - goes down Wtf
0 · Reply
Rambit
Rambit Jan. 13 at 4:35 PM
$BMRN Bit farther to 52/53 and I'll be back in 🙏
0 · Reply
DairyQueen505
DairyQueen505 Jan. 13 at 3:04 PM
$BMRN this is fucking ugly.
0 · Reply
tradeitbetit
tradeitbetit Jan. 12 at 11:16 PM
$BMRN psa do not trade this. Worst stock behavior in the market. No one cares about it
0 · Reply
DairyQueen505
DairyQueen505 Jan. 12 at 8:47 PM
$BMRN no love from Mr. Market today.
0 · Reply
DairyQueen505
DairyQueen505 Jan. 12 at 8:00 PM
$BMRN hit their FY revenue guidance and Voxzogo numbers. Check out the presentation. $100 soon.
0 · Reply
DairyQueen505
DairyQueen505 Jan. 12 at 4:27 PM
$BMRN presenting today. Should see financial results, update on acquisition, and BMN 351 update. 🚀
0 · Reply
svk33
svk33 Jan. 12 at 3:59 PM
$BMRN Here goes the bullflag-cons Probably for the gap at 52
2 · Reply
Stockprofiler
Stockprofiler Jan. 9 at 2:03 PM
$ACRV Acrivon Therapeutics Inc (ACRV) PT Raised at Piper Sandler on 'Positive Clinical Data' https://streetinsider.com/Analyst+Comments/Acrivon+Therapeutics+Inc+%28ACRV%29+PT+Raised+at+Piper+Sandler+on+Positive+Clinical+Data/25829378.html via @Street_Insider @Nasdaq Peers: $BMRN $VRTX
0 · Reply
tradeitbetit
tradeitbetit Jan. 8 at 9:10 PM
$BMRN how can year end turn into 2nd week of January without a single oops from the comoany. At least keep to your own promises f&/92k hate my decision to park my money here. #frustratedandbeyond #BMN351
0 · Reply
Ohzipit
Ohzipit Jan. 7 at 10:09 PM
$BMRN RJ repost from 12/19 and 12/22. Price target $100 Bull case $133
0 · Reply
DairyQueen505
DairyQueen505 Jan. 7 at 4:09 PM
$BMRN I'm sure. I'm feeling this is going to rip this year.
0 · Reply